Literature DB >> 27858465

Established and novel treatment options in acute myocarditis, with or without heart failure.

George Lazaros1, Evangelos Oikonomou1, Dimitris Tousoulis1.   

Abstract

INTRODUCTION: Acute myocarditis is a disorder characterized by an unpredictable clinical course which ranges from asymptomatic, incidentally discovered forms, to cases with fulminant course and adverse outcome. The most challenging issues in the context of acute myocarditis are the appearance of difficult to treat heart failure in the acute phase and the potential progression in the long-term to dilated cardiomyopathy. Areas covered: With respect to available treatment options in acute myocarditis, in the absence of specific guidelines, management is supportive and overall empirical, especially for the oligo- or asymptomatic patients with preserved ejection fraction. Haemodynamically instable patients should be treated in referral centers with capability of advanced cardiopulmonary support. Patients with heart failure but without haemodynamic impairment should be treated according to the heart failure guidelines. Endomyocardial biopsy may be performed in an individualized basis both for diagnostic purposes and to guide treatment, based on the detection or not of viral genome. Expert commentary: Apart from the already established treatments, novel therapies against several targets are currently investigated and are expected to contribute to a more efficacious management options in the future. Increased awareness among medical professionals is essential for the early diagnosis and best care of acute myocarditis patients.

Entities:  

Keywords:  Acute myocarditis; dilated cardiomyopathy; heart failure; infective cardiomyopathy; inflammatory cardiomyopathy; novel therapies; treatment options

Mesh:

Year:  2016        PMID: 27858465     DOI: 10.1080/14779072.2017.1262764

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  7 in total

Review 1.  Animal Models to Study Cardiac Arrhythmias.

Authors:  Daniel J Blackwell; Jeffrey Schmeckpeper; Bjorn C Knollmann
Journal:  Circ Res       Date:  2022-06-09       Impact factor: 23.213

Review 2.  Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis.

Authors:  Daowen Wang; Sheng Li; Jiangang Jiang; Jiangtao Yan; Chunxia Zhao; Yan Wang; Yexin Ma; Hesong Zeng; Xiaomei Guo; Hong Wang; Jiarong Tang; Houjuan Zuo; Li Lin; Guanglin Cui
Journal:  Sci China Life Sci       Date:  2018-12-03       Impact factor: 6.038

3.  Long non-coding RNA MEG3 inhibits M2 macrophage polarization by activating TRAF6 via microRNA-223 down-regulation in viral myocarditis.

Authors:  Yu-Long Xue; Sheng-Xiao Zhang; Chao-Feng Zheng; Yu-Feng Li; Li-Hui Zhang; Qin-Yi Su; Yu-Fei Hao; Shu Wang; Xue-Wen Li
Journal:  J Cell Mol Med       Date:  2020-10-13       Impact factor: 5.310

4.  Nursing effect of ECMO combined with CRRT in the treatment of fulminant myocarditis: A protocol of randomized controlled trial.

Authors:  Juan Wu; Hui Zhang; Yongxia Gao; Xihua Huang
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

5.  Overexpression of GATA binding protein 4 and myocyte enhancer factor 2C induces differentiation of mesenchymal stem cells into cardiac-like cells.

Authors:  Syeda Saima Razzaq; Irfan Khan; Nadia Naeem; Asmat Salim; Sumreen Begum; Kanwal Haneef
Journal:  World J Stem Cells       Date:  2022-09-26       Impact factor: 5.247

6.  Effect of PKC inhibitor on experimental autoimmune myocarditis in Lewis rats.

Authors:  Chunlian Zhong; Yang Wu; He Chang; Chunxiao Liu; Li Zhou; Jun Zou; Zhi Qi
Journal:  Oncotarget       Date:  2017-04-10

Review 7.  Dysregulated CD4+ T Cells and microRNAs in Myocarditis.

Authors:  Jing Wang; Bo Han
Journal:  Front Immunol       Date:  2020-03-25       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.